ClinicalTrials.gg
CompletedNCT04004507SNVUpdated Oct 30, 2026Results posted

Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances

A Phase 2 interventional study of Phentolamine Mesylate Ophthalmic Solution 1% and Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo) in Decrease in Night Vision and Disturbance; Vision, Loss, sponsored by Opus Genetics, Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Opus Genetics, Inc · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 11 years 10 months after the study started (first participant enrolled Aug 2007, registered Jun 2019).
Updated Oct 30, 2026Sponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The objectives of this study are:

  • To assess the effect of ophthalmic phentolamine mesylate in mesopic conditions on the four endpoints:

    1. Contrast sensitivity
    2. Low contrast visual acuity
    3. Wavefront aberrometry
    4. Subjective questionnaire
  • To assess the safety of ophthalmic phentolamine mesylate
Read the detailed description

Double-masked, placebo-controlled, single-dose Phase 2 study in 24 patients experiencing severe night vision difficulties to evaluate ocular and systemic safety and efficacy following administration of one drop of phentolamine mesylate 1.0% QD in each eye for 1 day.

02

Conditions studied

  • Decrease in Night Vision
  • Disturbance; Vision, Loss

Keywords

  • Night Vision Disturbances
  • NVD
  • Glare
  • Halos
  • Starbursts
  • Nyxol
03

In context

Lead sponsor

Opus Genetics, Inc is the lead sponsor of 17 studies on the registry; 4 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients ≥ 18 years of age
  2. Currently experiencing severe night vision difficulty as reported subjectively
  3. At least two patches below the normal range at any two frequencies in Contrast Sensitivity done under mesopic conditions with glare
  4. Improvement in low contrast visual acuity (LCVA) in dim light during illumination of contralateral eye
  5. Good general health
  6. Written to participate in this trial
  7. Ability to comply with all protocol mandated procedures and to attend all scheduled office visits

Exclusion criteria

Exclusion Criteria:

  1. Patients with untreated cataracts grades 1-4
  2. Patients who wear contact lenses
  3. Less than 5 weeks post-refractive surgery (LASIK or PRK)
  4. Less than 5 weeks post intraocular lens insertion
  5. Low blood pressure (systolic \<120 mm Hg or diastolic \<80 mm Hg)
  6. A history of heart rate abnormalities
  7. Administration of any drug within 30 days of study initiation
  8. Use of any eye drops with a pharmacologic effect on the pupil within 7 days of Visit 1
  9. Use of any systemic alpha adrenergic antagonists (Appendix 1)
  10. Known local or systemic to adrenergic antagonists
  11. For women of : currently pregnant or lactating, or unwilling to use during the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Phentolamine Mesylate Ophthalmic Solution 1%

    1 drop in each eye (QD) for one day.

    Drug: Phentolamine Mesylate Ophthalmic Solution 1%

  • Placebo comparator
    Phentolamine Mesylate Ophthalmic Solution Vehicle

    1 drop in each eye (QD) for one day.

    Other: Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)

Interventions

06

What researchers measure

Primary outcomes

  1. Contrast Sensitivity

    Average change in monocular contrast sensitivity scores under mesopic conditions at each of five spatial frequencies with and without glare. The tests were performed in a darkened room using the Optec 6500 instrument (Stereo Optical) using Slides 5-9 (spatial frequencies 1.5 - 18 cycles per degree), with the distance setting at "far", and with the light setting at "night". Subjects were asked to read each slide from left to right indicating if the lines were tilted to the left, the right or straight up and down until they provided 2 consecutive incorrect responses. The total number of correct responses for each slide was recorded.

    Time frame: 1 day

Secondary outcomes

  1. Visual Acuity

    Average number of letters of improvement in the following parameters: 1. Distance high-contrast visual acuity under mesopic conditions (monocular, measured at 4 meters) 2. Distance high-contrast visual acuity under photopic conditions (monocular, measured at 4 meters) 3. Distance low-contrast visual acuity under mesopic conditions (monocular, measured at 4 meters) 4. Distance low-contrast visual acuity under photopic conditions (monocular, measured at 4 meters)

    Time frame: 1 day

  2. Self-Reported Vision Quality

    Subjective patient evaluations of vision quality at night (% rating their vision as improved)

    Time frame: 1 day

  3. Pupil Diameter

    Average change in pupil diameter

    Time frame: 1 day

07

Results

Posted Feb 15, 2024

Participant flow

24 subjects were enrolled. Both eyes were treated and evaluated for efficay and safety.

Participant flow — Overall Study
MilestonePhentolamine Mesylate Ophthalmic Solution 1%Phentolamine Mesylate Ophthalmic Solution Vehicle
Started168
Completed168
Not completed00

Outcome measures

PrimaryContrast Sensitivity

Average change in monocular contrast sensitivity scores under mesopic conditions at each of five spatial frequencies with and without glare. The tests were performed in a darkened room using the Optec 6500 instrument (Stereo Optical) using Slides 5-9 (spatial frequencies 1.5 - 18 cycles per degree), with the distance setting at "far", and with the light setting at "night". Subjects were asked to read each slide from left to right indicating if the lines were tilted to the left, the right or straight up and down until they provided 2 consecutive incorrect responses. The total number of correct responses for each slide was recorded.

Time frame:
1 day
Reported as:
Mean · Patches
Contrast Sensitivity
PatchesPhentolamine Mesylate Ophthalmic Solution 1%Phentolamine Mesylate Ophthalmic Solution Vehicle
1.5 Cycles with Glare0.6 ± 1.80.8 ± 1.5
3 Cycles with Glare0.9 ± 2.10.7 ± 1.5
6 Cycles with Glare1.4 ± 1.90.1 ± 1.3
12 Cycles with Glare1.7 ± 2.00.4 ± 1.0
18 Cycles with Glare1.3 ± 1.80.3 ± 0.8
1.5 Cycles without Glare1.0 ± 1.40.4 ± 1.4
3 Cycles without Glare1.3 ± 1.50.7 ± 1.3
6 Cycles without Glare1.1 ± 1.40.5 ± 1.4
12 Cycles without Glare0.8 ± 1.6-0.2 ± 1.0
18 Cycles without Glare0.5 ± 1.40.3 ± 0.9
SecondaryVisual Acuity

Average number of letters of improvement in the following parameters: 1. Distance high-contrast visual acuity under mesopic conditions (monocular, measured at 4 meters) 2. Distance high-contrast visual acuity under photopic conditions (monocular, measured at 4 meters) 3. Distance low-contrast visual acuity under mesopic conditions (monocular, measured at 4 meters) 4. Distance low-contrast visual acuity under photopic conditions (monocular, measured at 4 meters)

Time frame:
1 day
Reported as:
Mean · Letters
Visual Acuity
LettersPhentolamine Mesylate Ophthalmic Solution 1%Phentolamine Mesylate Ophthalmic Solution Vehicle
Distance high-contrast visual acuity under mesopic conditions6.5 ± 7.21.1 ± 3.9
Distance high-contrast visual acuity under photopic conditions3.8 ± 7.60.1 ± 3.8
Distance low-contrast visual acuity under mesopic conditions8.0 ± 8.43.1 ± 4.5
Distance low-contrast visual acuity under photopic conditions7.3 ± 6.60.9 ± 3.6
SecondarySelf-Reported Vision Quality

Subjective patient evaluations of vision quality at night (% rating their vision as improved)

Time frame:
1 day
Reported as:
Number · Percentage
Self-Reported Vision Quality
PercentagePhentolamine Mesylate Ophthalmic Solution 1%Phentolamine Mesylate Ophthalmic Solution Vehicle
Self-Reported Vision Quality6975
SecondaryPupil Diameter

Average change in pupil diameter

Time frame:
1 day
Reported as:
Mean · mm
Pupil Diameter
mmPhentolamine Mesylate Ophthalmic Solution 1%Phentolamine Mesylate Ophthalmic Solution Vehicle
Pupil Diameter-1.3 ± 0.8-0.2 ± 0.5

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phentolamine Mesylate Ophthalmic Solution 1%—0/16 (0%)0/16 (0%)
Phentolamine Mesylate Ophthalmic Solution Vehicle—0/8 (0%)0/8 (0%)

Baseline characteristics

24 subjects were enrolled. Both eyes were evaluated for efficacy and safety.

Age, Continuous
Age, Continuous(years)Phentolamine Mesylate Ophthalmic Solution 1%Phentolamine Mesylate Ophthalmic Solution VehicleTotal
Mean42.1 ± 14.647.4 ± 13.543.9 ± 19.9
Sex: Female, Male
Sex: Female, Male(Participants)Phentolamine Mesylate Ophthalmic Solution 1%Phentolamine Mesylate Ophthalmic Solution VehicleTotal
Female12517
Male437
Pupil Diameter Illuminated
Pupil Diameter Illuminated(mm)Phentolamine Mesylate Ophthalmic Solution 1%Phentolamine Mesylate Ophthalmic Solution VehicleTotal
Mean4.4 ± 0.64.9 ± 0.84.6 ± 1
Trans-Illuminated Low Contrast Visual Acuity
Trans-Illuminated Low Contrast Visual Acuity(Letters)Phentolamine Mesylate Ophthalmic Solution 1%Phentolamine Mesylate Ophthalmic Solution VehicleTotal
Mean33.1 ± 5.430.1 ± 8.432.1 ± 10.0
08

Study locations

1 site
  • Ophthalmic Consultants of Long Island, NY
    Lynbrook, New York 11563, United States
09

References and documents

Publications

  • Pepose J, Brigell M, Lazar E, Heisel C, Yousif J, Rahmani K, Kolli A, Hwang M, Mitrano C, Lazar A, Charizanis K, Sooch M, McDonald M. A randomized phase 2 clinical trial of phentolamine mesylate eye drops in patients with severe night vision disturbances. BMC Ophthalmol. 2022 Oct 8;22(1):402. doi: 10.1186/s12886-022-02621-6. PubMed 36209072 ↗
10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2007 to primary completion in Oct 2007, 2 months.

Results were first posted in Feb 2024, 16 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2019
First posted
Jul 2, 2019
StartActual
Aug 2007
Primary completionActual
Oct 2007
CompletionActual
Feb 2008
Results first posted
Feb 15, 2024
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sponsor
Ocuphire Pharma, Inc.→Opus Genetics, Inc
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Sponsor Ocuphire Pharma, Inc.→Opus Genetics, Inc
    + 2 other changes: index terms and identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04004507
Lead sponsor
Opus Genetics, Inc
Collaborators
Ophthalmic Consultants of Long Island
Responsible party
Sponsor
First posted
Jul 2, 2019
Start date
Aug 2007
Primary completion
Oct 2007
Completion
Feb 2008
Results posted
Feb 15, 2024
Last update
Oct 30, 2026

Study contacts

Marguerite McDonald, MD, FACS
principal investigator · Ophthalmic Consultants of Long Island, NY

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Phentolamine

Start the discussion